MORRISVILLE, N.C.–(BUSINESS WIRE)–Arrivo BioVentures today announced positive data from its SP-624-103 study evaluating the impact of SP-624’s novel epigenetic mechanism of action on neurological pathways. The findings provide insights into the potential antidepressant and cognitive effects of SP-624, a SIRT6 activator that may be the first treatment specifically for females with Major Depression based on previous studies. Arrivo’s SP-624-103 study is a double blind, placebo-controlled study
Go to Source
Author: